Tag: clinical trials

Sale of Tox Lab Company Attracted Multiple Buyers

CEO SUMMARY: In the midst of expanding their toxicology testing services nationally, DrugScan and DSI Medical Services (collectively Toxicology Holdings Inc.) hired a brokerage firm last year to pursue a sale of the two toxicology companies. Multiple potential buyers responded with interest. The buyer, ACM Global Laboratories—owned by a health system in Rochester, N.Y.—saw the

View Article

To Grow Nationally, NY Lab Buys Tox Labs

CEO SUMMARY: It is unusual when a regional health system’s clinical lab company acquires a commercial lab company outside its geographic home. But that’s what happened in December when Rochester Regional Health System’s subsidiary, ACM Global Laboratories, acquired a toxicology testing lab and a pre-employment drug-screening company, both in Horsham, Pa., more than 300 miles

View Article

October 30, 2017 Intelligence: Late Breaking Lab News

Intelligence Late & Latent News

In a development that has implications for medical laboratories in developed nations, healthcare organizations in Africa have launched a “landmark electronic referral project” to digitally track workers who travel to South Africa to work in the mining industry. The project is being administered by TIMS (TB in the Mining Sector in South Africa). This digital medical

View Article

LabCorp Now Larger than Quest, Two Labs Report 2015 Earnings

IN RECENT WEEKS, the nation’s two largest lab companies reported fourth quarter and full-year earnings for 2015. The earnings reports reveal how the paths of the two companies are diverging.

The companies are diverging because of a major acquisition made in February 2015, by Laboratory Corporation of America. LabCorp bought Covance Inc. in a deal valued at

View Article

FDA Official Makes Case In Favor of LDT Guidance

CEO SUMMARY: Forty years ago, pathologists in hospital and academic labs worked closely with treating physicians to produce laboratory-developed tests for discrete clinical cases. Seeing that, the FDA decided not to regulate those tests, an FDA official said. Over time, however, use of LDTs became a serious concern when labs developing LDTs were no longer involved

View Article